Novel chemotherapies in development for management of castration-resistant prostate cancer.

Journal Article (Review)

Purpose of review

Four new therapies have been recently approved for the treatment of men with castration-resistant prostate cancer; still, more treatment options are needed. This review summarizes the data supporting a role for novel chemotherapies including epothilones and immunomodulators (IMiDs), as well as other novel agents within the new landscape of approved therapies.

Recent findings

Epothilones are a class of chemotherapy that target microtubule disassembly, similar to taxanes. Results from phase II studies demonstrating a positive impact on serum prostate-specific antigen for patupilone and sagopilone, current epothilones in development, along with those of ixabepilone, are comparable with historical response rates to docetaxel, the current first-line chemotherapy for castration-resistant disease. IMiDs, including lenalidamide and thalidomide, are also in active development in castration-resistant prostate cancer. A recent phase III study evaluating the combination of lenalidomide and docetaxel revealed decreased overall survival relative to docetaxel alone; however, additional trials are currently recruiting to investigate lenalidomide in various other combination regimens.

Summary

Epothilones could be efficacious as an additional therapy in patients who respond to docetaxel chemotherapy. A role for IMiDs, perhaps in combination with chemotherapy or androgen pathway inhibitors, remains to be elucidated.

Full Text

Duke Authors

Cited Authors

  • Tewari, AK; George, DJ

Published Date

  • May 2013

Published In

Volume / Issue

  • 23 / 3

Start / End Page

  • 220 - 229

PubMed ID

  • 23511791

Pubmed Central ID

  • 23511791

Electronic International Standard Serial Number (EISSN)

  • 1473-6586

International Standard Serial Number (ISSN)

  • 0963-0643

Digital Object Identifier (DOI)

  • 10.1097/mou.0b013e32835f7da2

Language

  • eng